This site is intended for Healthcare Professionals only.

AstraZeneca to stop developing Crohn’s disease drug


Share post:

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

The company said the discontinuation was due to a delay in the drug’s development timeline, affected by global events and “the context of a competitive landscape”.

AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie’s $63 billion tie-up with Allergan.

AbbVie will stop funding the drug’s development, AstraZeneca said.

AbbVie’s Skyrizi also treats Crohn’s disease.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

Knights Pharmacy expands footprint in South Wales with acquisition of 2 new pharmacies

Knights pharmacy to provide independent prescribing services at the new locations in South Wales Knights Pharmacy has significantly expanded...

Pharmacy bodies respond to Labour Party manifesto promises on community pharmacy

Pharmacy leaders have urged funding boost for pharmacies in response to Labour's ambitious healthcare plans The Labour Party's election...

RPS calls on political leaders to end prescription charges for long-term conditions

RPS and PCC urge political leaders to urgently get rid of prescription charges for chronic conditions on the...

Corsodyl unveils new toothpaste and mouthwash range targeted at preventing gum problems

New Corsodyl Gum Strength & Protect line includes clinically proven formulas to enhance gum health and prevent issues With...